Claims for Patent: 10,500,273

Summary for Patent: 10,500,273

Title:	Method of treating a localized fibrotic disorder using an IL-33 antagonist
Abstract:	The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.
Inventor(s):	Larsen; Glenn (Sudbury, MA), Nanchahal; Jagdeep (Headington, GB), Feldmann; Marc (London, GB)
Assignee:	180 Therapeutics LP (Cambridge, MA)
Application Number:	15/555,027
Patent Claims:	1. A method of treating a patient suffering from early disease stage Dupuytren's disease which comprises administering locally at the site of the early disease stage of Dupuytren's disease in the patient, an IL-33 antagonist which is an antibody that specifically binds to, and inhibits activation of, an IL-33 receptor or a binding fragment of such an antibody that specifically binds to and inhibits activation of an IL-33 receptor in an amount effective to downregulate expression of alpha-SMA, ST2 and COL1A1 in the patient's myofibroblasts so as to thereby treat the patient. 2. The method of claim 1 wherein the IL-33 antagonist is injected to a site of maximal cellularity or maximal inflammation. 3. The method of claim 1 wherein the effective amount of the IL-33 antagonist is an amount between 0.1 mg and 500 mg. 4. A method of claim 1, which further comprises co-administering a TNF-.alpha. antagonist. 5. The method of claim 4, wherein the amount of the TNF-.alpha. antagonist is between 5 mg and 300 mg. 6. The method of claim 4, wherein the TNF-.alpha. antagonist is one or more of infliximab, adalimumab, certolizumab pegol, golimumab or etanercept. 7. The method of claim 6, wherein the TNF-.alpha. antagonist is golimumab and the amount of golimumab administered is between 1 mg and 90 mg. 8. The method of claim 6, wherein the TNF-.alpha. antagonist is adalimumab and the amount of adalimumab administered is between 5 mg and 100 mg. 9. The method of claim 6, wherein the TNF-.alpha. antagonist is certolizumab pegol and the amount of certolizumab pegol administered is between 50 mg and 200 mg. 10. The method of claim 6, wherein the TNF-.alpha. antagonist is infliximab and the amount of infliximab administered is between 50 mg and 300 mg. 11. The method of claim 6, wherein the TNF-.alpha. antagonist is etanercept and the amount of etanercept administered is between 5 mg and 50 mg. 12. The method of claim 4, wherein the TNF-.alpha. antagonist is a TNF receptor 2 (TNFR2) antagonist. 13. The method of claim 1, wherein the antibody is a chimeric antibody, a humanized antibody, or a human antibody.

Details for Patent 10,500,273

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2035-03-02
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2035-03-02
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2035-03-02
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2035-03-02